-

Kardium Receives CE Mark for Globe® Mapping and Ablation System

Announces launch of commercial sales in Europe

VANCOUVER, British Columbia--(BUSINESS WIRE)--Kardium Inc. has received CE mark approval for its Globe Mapping and Ablation System – the most complete solution for the treatment of atrial fibrillation (AF). AF is the world’s most common heart rhythm disorder, affecting more than 37 million people. This approval allows Kardium to begin commercial sales of the Globe System in Europe.

“This is an important milestone both for Kardium and the global AF community,” said Kevin Chaplin, CEO of Kardium. “The Globe System can now be used by electrophysiologists (EPs) across Europe to safely and effectively treat patients with AF. We have a sales and support team in place and are now launching the Globe System for clinical use in Europe.”

The spherical Globe catheter has 122 electrodes and, when combined with the Globe System’s sophisticated software, is the only device that provides the EP with single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation, giving the most complete solution for treating AF.

“The Globe Mapping and Ablation System has the potential to completely revolutionize the way we treat atrial fibrillation,” said Prof. Hans Kottkamp, Head of Electrophysiology, Sana Hospitals, Düsseldorf. “By combining single-shot ablation with high-resolution mapping and the ability to ablate anywhere in the left atrium, the Globe System gives us a comprehensive solution to treat both paroxysmal and persistent AF.”

The CE mark approval was based on the positive results from the GLOBAL-AF study, a multi-centre study that demonstrated the safety and effectiveness of the Globe Mapping and Ablation System.

Kardium GmbH has been formed in Dortmund, Germany to handle commercial sales of the Globe System in Europe.

ABOUT KARDIUM

Kardium Inc. (kardium.com) is a rapidly growing medical solutions company that has developed an advanced system for the treatment of atrial fibrillation: the Globe Mapping and Ablation System. Kardium has built an outstanding team of engineers, medical researchers, compliance and production staff who have worked with top medical advisors to develop the Globe System. Founded in 2007 and headquartered in Vancouver, Canada, Kardium has consistently ranked as one of the top companies to work for in British Columbia.

Contacts

Kevin Chaplin, CEO, Kardium Inc.
+1-604-248-8891 x 277 | kevin.chaplin@kardium.com

Kardium Inc.


Release Versions

Contacts

Kevin Chaplin, CEO, Kardium Inc.
+1-604-248-8891 x 277 | kevin.chaplin@kardium.com

More News From Kardium Inc.

Kardium Announces First Commercial Procedures with the Globe® Pulsed Field System, the World’s Most Advanced Solution for Atrial Fibrillation

VANCOUVER, British Columbia--(BUSINESS WIRE)--Kardium, a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), today announced the successful completion of the first commercial procedures using its integrated mapping and ablation system, the Globe Pulsed Field System, following recent approval from the U.S. Food and Drug Administration (FDA). The inaugural U.S. procedures were performed by Dr. Devi Nair, Chief of Cardiac Electrophysiology and EP Rese...

Kardium receives FDA approval of the Globe® Pulsed Field System

VANCOUVER, British Columbia--(BUSINESS WIRE)--Kardium Inc., a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), announced today it has received pre-market approval (PMA) for the Globe® Pulsed Field System and 510(k) clearance for both the Globe® Introducer sheath and the Globe® Pulsed Field System mapping software from the U.S. Food and Drug Administration (FDA). The Globe System is the only integrated, high-density cardiac mapping and ablation s...

Kardium Announces $250M (CA$340M) Financing to Launch Innovative Atrial Fibrillation Treatment

VANCOUVER, British Columbia--(BUSINESS WIRE)--Kardium Inc., the developer of the Globe® Pulsed Field System – an innovative treatment for atrial fibrillation (AF) – has raised US$250 million in a new financing round. The oversubscribed round was led by new investors including Janus Henderson Investors, Qatar Investment Authority (QIA), MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital. Existing investors also participated, including funds and accounts adv...
Back to Newsroom